MicroRNA in alcoholic hepatitis: Implications for pathophysiology and treatment

Gut

Volumn 65, Issue 9, 2016, Pages 1400-1401

  Stickel, Felix ^a   Dubuquoy, Laurent ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; FARNESOID X RECEPTOR; MICRORNA; MICRORNA 155; MICRORNA 182; MICRORNA 21; MICRORNA 214; MICRORNA 422; PREGNAN X RECEPTOR; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ALCOHOL LIVER DISEASE; CAUSAL ATTRIBUTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TARGETING; HUMAN; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RNA ANALYSIS; ALCOHOL LIVER CIRRHOSIS; GENETICS; LIVER;

HEPATITIS, ALCOHOLIC; HUMANS; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; MICRORNAS;

EID: 84973377032     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-312101     Document Type: Note

References (12)

1. Trabut JB, Plat A, Thepot V, et al. Influence of liver biopsy on abstinence in alcohol-dependent patients. Alcohol Alcohol 2008;43:559-63.
2. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-9.
3. Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol 2015;62(1 Suppl):S38-46.
4. Murakami Y, Kawada N. MicroRNAs in hepatic pathophysiology. Hepatol Res Published Online First: 21 Apr 2016. doi: 10.1111/hepr.12730
5. Dolganiuc A, Petrasek J, Kodys K, et al. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res 2009;33:1704-10.
6. Bala S, Csak T, Saha B, et al. The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol 2016; 4:1378-87.
7. Blaya D, Coll M, Rodrigo-Torres D, et al. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut 2016;65:1535-45.
8. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebocontrolled trial. Lancet 2015;385:956-65.
9. Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015;148:751-61e8.
10. Atkinson S, Way M, McQuillin A, et al. A Genome-wide association study identifies PNPLA3 and SLC38A4 as risk loci for alcoholic hepatitis. J Hepatol 2016;64(Suppl 2):S134, GS03.
11. Chen L, Ma H, Hu H, et al. Special role of Foxp3 for the specifically altered microRNAs in regulatory T cells of HCC patients. BMC Cancer 2014;14:489.
12. Dubuquoy L, Louvet A, Lassailly G, et al. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut 2015;64:1949-60.